✦ LIBER ✦

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer

✍ Scribed by Takashi Kobayashi; Tomonobu Koizumi; Toshihide Agatsuma; Masanori Yasuo; Kenji Tsushima; Keishi Kubo; Seiichiro Eda; Hiroshi Kuraishi; Shigeru Koyama; Tsutomu Hachiya; Nariaki Ohura

Book ID: 113028060
Publisher: Springer
Year: 2012
Tongue: English
Weight: 271 KB
Volume: 69
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-012-1831-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase II Trial of Onartuzumab

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

✍ Spigel, D. R.; Ervin, T. J.; Ramlau, R. A.; Daniel, D. B.; Goldschmidt, J. H.; B 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 266 KB

20 A single centre experience of erlotin

20 A single centre experience of erlotinib in unselected and wild type EGFR patients with non small cell lung cancer

✍ Walter, H.S.; Ahmed, S.I. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Erlotinib versus docetaxel as second-lin

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

✍ Garassino, Marina Chiara; Martelli, Olga; Broggini, Massimo; Farina, Gabriella; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 279 KB

Phase III Trial of Vandetanib Compared W

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

✍ Natale, R. B.; Thongprasert, S.; Greco, F. A.; Thomas, M.; Tsai, C.-M.; Sunpawer 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 298 KB

A phase II trial with RFS2000 (rubitecan

A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer

✍ S. Baka; M. Ranson; P. Lorigan; S. Danson; K. Linton; I. Hoogendam; K. Mettinger 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 82 KB

9150 Phase I trial of vorinostat in comb

9150 Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression (NCT00503971): The TARZO trial

✍ Reguart, N.; Isla, D.; Cardona, A.F.; Palmero, R.; Cardenal, F.; Rolfo, C.; Mont 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB